Use of low-molecular-weight heparins during percutaneous coronary intervention

Jack L. Martin, Marvin J Slepian

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with acute coronary syndromes (ACS) may transition to percutaneous coronary intervention (PCI) after an initial phase of medical management that includes anticoagulation. When patients come to the catheterization laboratory, it is important to consider previously received anticoagulation. Enoxaparin has emerged as a more effective, yet simple, agent for use in the emergency room or upon initial encounter of the ACS patient. However, there may be uncertainty among physicians on the adequacy and way to use anticoagulation in the transition to the catheterization laboratory. Recently, new data have emerged on the use of enoxaparin in the catheterization laboratory. Dosing schedules based on pharmacodynamic and clinical data offer a seamless transition for enoxaparin from the medical management phase to PCI. In this paper, the pharmacokinetics of enoxaparin are reviewed and recommendations for anticoagulant regimens provided based upon the timing of presentation and pre-catheterization dosing.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalJournal of Invasive Cardiology
Volume23
Issue number1
StatePublished - Jan 2011

Fingerprint

Enoxaparin
Low Molecular Weight Heparin
Percutaneous Coronary Intervention
Catheterization
Acute Coronary Syndrome
Anticoagulants
Uncertainty
Hospital Emergency Service
Appointments and Schedules
Pharmacokinetics
Physicians

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Use of low-molecular-weight heparins during percutaneous coronary intervention. / Martin, Jack L.; Slepian, Marvin J.

In: Journal of Invasive Cardiology, Vol. 23, No. 1, 01.2011, p. 1-8.

Research output: Contribution to journalArticle

@article{416a84ccd6324ced8a907559bdb2e97c,
title = "Use of low-molecular-weight heparins during percutaneous coronary intervention",
abstract = "Patients with acute coronary syndromes (ACS) may transition to percutaneous coronary intervention (PCI) after an initial phase of medical management that includes anticoagulation. When patients come to the catheterization laboratory, it is important to consider previously received anticoagulation. Enoxaparin has emerged as a more effective, yet simple, agent for use in the emergency room or upon initial encounter of the ACS patient. However, there may be uncertainty among physicians on the adequacy and way to use anticoagulation in the transition to the catheterization laboratory. Recently, new data have emerged on the use of enoxaparin in the catheterization laboratory. Dosing schedules based on pharmacodynamic and clinical data offer a seamless transition for enoxaparin from the medical management phase to PCI. In this paper, the pharmacokinetics of enoxaparin are reviewed and recommendations for anticoagulant regimens provided based upon the timing of presentation and pre-catheterization dosing.",
author = "Martin, {Jack L.} and Slepian, {Marvin J}",
year = "2011",
month = "1",
language = "English (US)",
volume = "23",
pages = "1--8",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "1",

}

TY - JOUR

T1 - Use of low-molecular-weight heparins during percutaneous coronary intervention

AU - Martin, Jack L.

AU - Slepian, Marvin J

PY - 2011/1

Y1 - 2011/1

N2 - Patients with acute coronary syndromes (ACS) may transition to percutaneous coronary intervention (PCI) after an initial phase of medical management that includes anticoagulation. When patients come to the catheterization laboratory, it is important to consider previously received anticoagulation. Enoxaparin has emerged as a more effective, yet simple, agent for use in the emergency room or upon initial encounter of the ACS patient. However, there may be uncertainty among physicians on the adequacy and way to use anticoagulation in the transition to the catheterization laboratory. Recently, new data have emerged on the use of enoxaparin in the catheterization laboratory. Dosing schedules based on pharmacodynamic and clinical data offer a seamless transition for enoxaparin from the medical management phase to PCI. In this paper, the pharmacokinetics of enoxaparin are reviewed and recommendations for anticoagulant regimens provided based upon the timing of presentation and pre-catheterization dosing.

AB - Patients with acute coronary syndromes (ACS) may transition to percutaneous coronary intervention (PCI) after an initial phase of medical management that includes anticoagulation. When patients come to the catheterization laboratory, it is important to consider previously received anticoagulation. Enoxaparin has emerged as a more effective, yet simple, agent for use in the emergency room or upon initial encounter of the ACS patient. However, there may be uncertainty among physicians on the adequacy and way to use anticoagulation in the transition to the catheterization laboratory. Recently, new data have emerged on the use of enoxaparin in the catheterization laboratory. Dosing schedules based on pharmacodynamic and clinical data offer a seamless transition for enoxaparin from the medical management phase to PCI. In this paper, the pharmacokinetics of enoxaparin are reviewed and recommendations for anticoagulant regimens provided based upon the timing of presentation and pre-catheterization dosing.

UR - http://www.scopus.com/inward/record.url?scp=79954433910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954433910&partnerID=8YFLogxK

M3 - Article

C2 - 21183762

AN - SCOPUS:79954433910

VL - 23

SP - 1

EP - 8

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 1

ER -